Metraipolis › archive › dc_a281baca8a92
Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer — Europe PMC PMID:42795776
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42795776
- DOI
- 10.3390/jcm15187004
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-10T05:04:29.562Z
- SHA-256 of the archived text
f1c9abf7a0cad14fa04aeebccf7a71b4723c3f7394f8bc941c413985e7b8fb30- Stable URL of this page
https://metraipolis.com/documento/dc_a281baca8a92
How to cite
Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer — Europe PMC PMID:42795776 — Europe PMC (en), https://europepmc.org/article/MED/42795776 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a281baca8a92 (Metraipolis archive dc_a281baca8a92, sha256 f1c9abf7a0cad14fa04aeebccf7a71b4723c3f7394f8bc941c413985e7b8fb30)
BibTeX
@misc{dca281baca8a92,
title = {Aprepitant, a Neurokinin-1 Receptor Antagonist, as a Disruptive Drug for the Treatment of Pediatric Cancer — Europe PMC PMID:42795776},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42795776},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a281baca8a92; sha256 f1c9abf7a0cad14fa04aeebccf7a71b4723c3f7394f8bc941c413985e7b8fb30},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42795776. Agents can read the archived copy with the MCP tool read_document.